Loi et al. also focused on TILs in the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy and demonstrated that MEK inhibition upregulated PD-L1 expression in TNBC cells with lower TILs, suggesting the possible combination use of MEK inhibitor and ICI37. The gene discussed is MAP2K7; the disease is triple-negative breast carcinoma.